Anti-Tumour Effects of a Specific Anti-ADAM17 Antibody in an Ovarian Cancer Model In Vivo

Frances M. Richards, Christopher J. Tape, Duncan I. Jodrell, Gillian MurphyPLoS 2012 · DOI

Abstract

ADAM 17 (TNF-α converting enzyme, TACE) is a potential target for cancer therapy, but the small molecule inhibitors reported to date are not specific to this ADAM family member. This membrane-bound metalloproteinase is responsible for ectodomain shedding of pathologically significant substrates including TNF-α and EGFR ligands. The aim of this study was to evaluate the pharmacokinetics, pharmacodynamics and anti-tumour efficacy of the first specific inhibitor, an anti-human ADAM17 IgG antibody, clone D1(A12). We used intraperitoneal xenografts of the human ovarian cancer cell line IGROV1-Luc in Balb/c nude mice. In vitro, 200 nM D1(A12) inhibited shedding of ADAM17 substrates TNF-α, TNFR1-α, TGF-α, amphiregulin (AREG), HB-EGF and IL-6Rα from IGROV1-Luc cells. In vivo, D1(A12) IgG showed a significant reduction in tumour growth (p = 0.005), reaching 56% of vehicle control. D1(A12) showed clear pharmacodynamic effects in the mice, with significant inhibition of shedding from tumour of ADAM17 substrates TNFR1-α, AREG, and TGF-α (4-15-fold reductions). Thus, D1(A12) has anti-ADAM17 activity in vivo, inhibits shedding of EGFR ligands, and has potential for use in EGF ligand-dependent tumours.

Introduction

Many cancers rely on "ectodomain shedding," a process where membrane-bound signaling proteins are released into the extracellular environment. The enzyme ADAM17 (A Disintegrin And Metalloproteinase 17), also known as TNF-α converting enzyme (TACE), acts as "molecular scissors" for these proteins. Once released, substrates like TNF-α and various Epidermal Growth Factor Receptor (EGFR) ligands can drive inflammation and rapid tumor proliferation.

While ADAM17 is a promising therapeutic target, previous small-molecule inhibitors lacked specificity, often hitting other enzymes like ADAM10 or Matrix Metalloproteinases (MMPs). This lack of selectivity led to severe side effects in clinical trials. This study investigates whether a highly specific antibody, D1(A12), can effectively inhibit ADAM17 in vivo without the toxicity associated with broad-spectrum inhibitors.

Methods

The researchers evaluated the human anti-ADAM17 IgG antibody, clone D1(A12), using the following experimental framework:

  • In Vitro Assays: The IGROV1-Luc human ovarian cancer cell line was used to measure the antibody's ability to block the shedding of substrates (TNF-α, TNFR1, TGF-α, etc.) under stimulation.
  • Xenograft Model: Luciferase-tagged IGROV1 cells were implanted into the peritoneal cavity of Balb/c nude mice.
  • Bioluminescence Imaging: Tumor burden was tracked non-invasively over time using an IVIS imaging system to detect the luciferase signal.
  • Pharmacokinetics (PK) & Pharmacodynamics (PD): Antibody concentrations were measured in plasma and ascites fluid. PD effects were assessed by measuring levels of shed proteins via ELISA to confirm target engagement within the animal.

Results

Potency and Pharmacokinetics

In cell culture, D1(A12) demonstrated high potency with an $IC_{50}$ of 4.7 nM for inhibiting TNF-α shedding. In the mouse model, the antibody showed favorable pharmacokinetic properties suitable for weekly dosing, with a plasma half-life of 8.6 days. A single 10 mg/kg dose maintained concentrations above 100 nM in both plasma and ascites for over a week.

Anti-Tumor Efficacy

Treatment with D1(A12) (10 mg/kg weekly) resulted in a significant reduction in tumor growth, with the tumor burden reaching only 56% of the vehicle control (p = 0.005).

Pharmacodynamic Insights

The antibody achieved a 4- to 15-fold reduction in the shedding of TNFR1, AREG, and TGF-α into the abdominal fluid of the mice. Interestingly, while the antibody perfectly blocked TNF-α shedding in vitro, circulating human TNF-α levels in the living mice did not drop significantly. This suggests a "compensation effect" where other enzymes, such as ADAM10, may take over TNF-α shedding when ADAM17 is specifically inhibited in a complex in vivo environment.

Discussion

The study demonstrates that specific inhibition of ADAM17 is a viable strategy for reducing tumor growth. The anti-tumor effect appears to be driven primarily by the inhibition of EGFR ligand shedding (like TGF-α and AREG) rather than TNF-α suppression alone.

However, the efficacy was described as "modest," which the authors attribute to two main factors. First, immunohistochemistry revealed that the antibody struggled to penetrate deep into the tumor mass, remaining largely near the blood vessels. Second, enzymatic redundancy (e.g., ADAM10) may limit the impact of targeting a single "sheddase." Future therapeutic strategies might involve smaller antibody fragments for better penetration or "cocktail" approaches targeting multiple ADAM family members to overcome compensatory mechanisms.

Summary updated

Abstract

ADAM 17 (TNF-α converting enzyme, TACE) is a potential target for cancer therapy, but the small molecule inhibitors reported to date are not specific to this ADAM family member. This membrane-bound metalloproteinase is responsible for ectodomain shedding of pathologically significant substrates including TNF-α and EGFR ligands. The aim of this study was to evaluate the pharmacokinetics, pharmacodynamics and anti-tumour efficacy of the first specific inhibitor, an anti-human ADAM17 IgG antibody, clone D1(A12). We used intraperitoneal xenografts of the human ovarian cancer cell line IGROV1-Luc in Balb/c nude mice, chosen because it was previously reported that growth of these xenografts is inhibited by knock-down of TNF-α. In vitro, 200 nM D1(A12) inhibited shedding of ADAM17 substrates TNF-α, TNFR1-α, TGF-α, amphiregulin (AREG), HB-EGF and IL-6Rα, from IGROV1-Luc cells, (4.7 nM IC(50) for TNF-α shedding). In IGROV1-Luc xenografts in vivo, D1(A12) IgG showed pharmacokinetic properties suitable for efficacy studies, with a single i.p. dose of 10 mg/kg D1(A12) sufficient to maintain IgG plasma and ascites fluid concentrations above 100 nM for more than 7 days. The plasma half life was 8.6 days. Next, an efficacy study was performed, dosing D1(A12) or anti-human TNF-α antibody infliximab at 10 mg/kg q7d, quantifying IGROV1-Luc tumour burden by bioluminescence. D1(A12) IgG showed a significant reduction in tumour growth (p = 0.005), 56% of vehicle control. Surprisingly, D1(A12) did not reduce the concentration of circulating human TNF-α, suggesting that another enzyme may compensate for inhibition of ADAM17 in vivo (but not in vitro). However, D1(A12) did show clear pharmacodynamic effects in the mice, with significant inhibition of shedding from tumour of ADAM17 substrates TNFR1-α, AREG, and TGF-α (4-15-fold reductions, p<0.0001 for all three). Thus, D1(A12) has anti-ADAM17 activity in vivo, inhibits shedding of EGFR ligands and has potential for use in EGF ligand-dependent tumours.
BibTeX
@inproceedings{richards2012anti,
  author = {Frances M. Richards and Christopher J. Tape and Duncan I. Jodrell and Gillian Murphy},
  title = {{Anti-Tumour Effects of a Specific Anti-ADAM17 Antibody in an Ovarian Cancer Model In Vivo}},
  booktitle = {PLoS},
  year = {2012},
  doi = {10.1371/journal.pone.0040597},
}
Figure